Partnering with AI|ffinity

At Affinity, we are pioneers in leveraging the synergy of nuclear magnetic resonance (NMR) and artificial intelligence (AI) to forge unprecedented pathways in drug development. We target a wide array of proteins, including those considered previously undruggable, such as intrinsically disordered proteins (IDPs). We are particularly interested in collaborations involving pre-clinical drug development (hit identification, lead optimization, preclinical candidate selection), with a special focus on IDPs and proteins less than 30 kilodaltons (kDa). The 30 kDa limit, although not necessary to conduct drug design, enables us to employ our 4D NMR technology for rapid structure determination of protein-ligand complexes to give us helpful insights for rational drug design.

We are also interested in nanobody design and structure determination of soluble proteins below 30 kDa, with a particular interest in proteins of diverse origin and fold.

Finally, we warmly welcome proposals for joint method and software development focused on drug design or NMR structure determination. If you would like to collaborate with AI|ffinity, please provide us with a non-confidential proposal along with scientific supporting data to: tevang@aiffinity.com